These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 18319488)
1. Diabetes specialists keep ACCORD data in perspective. Traynor K Am J Health Syst Pharm; 2008 Mar; 65(6):488, 490. PubMed ID: 18319488 [No Abstract] [Full Text] [Related]
2. A summary of the ADVANCE Trial. Heller SR; Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581 [No Abstract] [Full Text] [Related]
3. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? Lipska KJ; Krumholz HM JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758 [No Abstract] [Full Text] [Related]
4. Type 2 diabetes: target HbA1c of about 7%. Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575 [TBL] [Abstract][Full Text] [Related]
5. Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes. Martin CL Diabetes Educ; 2007; 33 Suppl 1():6S-13S. PubMed ID: 17272803 [No Abstract] [Full Text] [Related]
6. United Kingdom prospective diabetes study: a different perspective. Kabadi UM Endocr Pract; 2002; 8(1):61-4. PubMed ID: 11939763 [No Abstract] [Full Text] [Related]
7. [Different strategies in prediabetes, new and long-time diabetes. What therapy for what diabetics?]. Stiefelhagen P MMW Fortschr Med; 2010 Jan; 152(3):12-4, 16. PubMed ID: 20333958 [No Abstract] [Full Text] [Related]
9. Should we use intensive insulin therapy after oral agent failure in type II diabetes? Colwell JA Diabetes Care; 1996 Aug; 19(8):896-8. PubMed ID: 8842613 [No Abstract] [Full Text] [Related]
10. Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence? Boussageon R; Gueyffier F; Cornu C Diabetes Metab; 2014 Jun; 40(3):169-75. PubMed ID: 24503191 [TBL] [Abstract][Full Text] [Related]
12. [Aggressive and early combined drug therapy. Antidiabetics for prevention of myocardial infarct]. MMW Fortschr Med; 2003 Jun; 145(25):52. PubMed ID: 12891856 [No Abstract] [Full Text] [Related]
13. Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians. Dhar GC Can Fam Physician; 2009 Aug; 55(8):803-4. PubMed ID: 19675265 [No Abstract] [Full Text] [Related]
14. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Riddle MC Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472 [No Abstract] [Full Text] [Related]
15. Tight glycaemic control and cardiovascular disease in type 2 diabetes. Demssie YN; Soran H; Younis N Br J Hosp Med (Lond); 2009 Jan; 70(1):31-2, 34. PubMed ID: 19357575 [TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes and HbA1c targets. Prescrire Int; 2008 Dec; 17(98):254. PubMed ID: 19425272 [TBL] [Abstract][Full Text] [Related]
18. [Certain beginning of insulin therapy: yes, we can, but...]. Rohrer A Praxis (Bern 1994); 2009 Mar; 98(6):301. PubMed ID: 19338117 [No Abstract] [Full Text] [Related]
19. Safety of very tight glucose control in type 2 diabetes in question. Idris I Diabetes Obes Metab; 2008 May; 10(5):438. PubMed ID: 18431839 [No Abstract] [Full Text] [Related]